Close X
Attorney Spotlight

How did Brianna Powell's work as a law clerk prepare her for practicing law? Read more>

Search

Close X

Experience

Search our Experience

Experience Spotlight

In June 2017, Pinnacle Financial Partners, Inc. (NASDAQ: PNFP) closed a $1.9 billion merger with BNC Bancorp (NASDAQ: BNCN) pursuant to which BNC merged with and into Pinnacle. With the completion of the transaction, Pinnacle becomes a Top 50 U.S. Bank. The merger will create a four state footprint concentrated in 12 of the largest urban markets in the Southeast. 

Bass, Berry & Sims has served Pinnacle as primary corporate and securities counsel for more than 15 years and served as counsel on the transaction. Our attorneys were involved in all aspects related to the agreement, including tax, employee benefits and litigation. 

Read more details about the transaction here.

Pinnacle Financial Partners logo

Close X

Thought Leadership

Enter your search terms in the relevant box(es) below to search for specific Thought Leadership.
To see a recent listing of Thought Leadership, click the blue Search button below.

Thought Leadership Spotlight

Regulation A+

It seems that lately there has been a noticeable uptick in Regulation A+ activity, including several recent Reg A+ securities offerings where the stock now successfully trades on national exchanges. In light of this activity, we have published a set of FAQs about Regulation A+ securities offerings to help companies better understand this "mini-IPO" offering process, as well as pros and cons compared to a traditional underwritten IPO.

Read now

Emergent BioSolutions Completes Two Acquisitions of Medical Countermeasures to Supply the U.S. Strategic National Stockpile

Client Type: Public Company

We advised Emergent BioSolutions (NYSE:EBS) on the government contract aspects of two transactions involving the acquisition of assets related to medical countermeasures used by the U.S. government. These transactions expand Emergent's portfolio of approved medical countermeasures addressing Category A bioterrorism threats.

Emergent BioSolutions purchased the assets related to raxibacumab, a countermeasure approved by the U.S. Food and Drug Administration (FDA) for the treatment and prophylaxis of inhalational anthrax, from GlaxoSmithKline (LSE/NYSE:GSK). Emergent will assume responsibility for GSK's multi-year supply contract with the Biomedical Advanced Research and Development Authority (BARDA) for raxibacumab, which will be used to further supply the U.S. Strategic National Stockpile (SNS). BARDA, a division of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, procures antibiotics, vaccines, chemical antidotes, antitoxins, and other critical equipment and supplies for the SNS.

Emergent BioSolutions also purchased the assets related to ACAM2000®, (Smallpox (Vaccinia) Vaccine, Live), the only FDA-approved smallpox vaccine, from Sanofi. Emergent will assume responsibility for an existing 10-year contract with the Centers for Disease Control and Prevention (CDC) for the delivery of ACAM2000 to the SNS and establishing U.S.-based manufacturing of ACAM2000. More than 230 million doses have been supplied to the SNS to date.

Emergent BioSolutions is a global life sciences company that seeks to protect and enhance life by focusing on providing medical countermeasures for civilian and military populations that address accidental, intentional, and naturally emerging public health threats.

You Also May Be Interested In:

Related Professionals

Related Services

Notice

Visiting, or interacting with, this website does not constitute an attorney-client relationship. Although we are always interested in hearing from visitors to our website, we cannot accept representation on a new matter from either existing clients or new clients until we know that we do not have a conflict of interest that would prevent us from doing so. Therefore, please do not send us any information about any new matter that may involve a potential legal representation until we have confirmed that a conflict of interest does not exist and we have expressly agreed in writing to the representation. Until there is such an agreement, we will not be deemed to have given you any advice, any information you send may not be deemed privileged and confidential, and we may be able to represent adverse parties.